FesariusTherapeutics is a commercial-stage medical technology company headquartered in New York whose flagship product, DermiSphere™, is the first hydrogel Dermal Regeneration Template (hDRT) cleared by the FDA (510(k) clearance in January 2025). DermiSphere™ features a patented dual-density collagen microarchitecture intended to facilitate cellular integration and vascularization to support wound healing. The device is commercially active across multiple U.S. hospital systems and the company reports growing clinical momentum. Fesarius plans to pursue Breakthrough Device Designation, expanded reimbursement pathways, and a pivotal clinical trial supporting a OneStep procedure and future label expansion. The company will use proceeds from its $20 million Series A to accelerate commercial infrastructure and expand its national direct sales coverage. The financing included strategic and institutional investors, signaling validation from both corporate and specialty-society backers.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2026